MedTrace Logo

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH

NCT00607633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 686

Last updated 2008-02-06

No results posted yet for this study

Summary

The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

Conditions

  • Essential Hypertension
  • Left Ventricular Hypertrophy

Sponsors & Collaborators

Principal Investigators

  • F. Sonntag, MD · Cardiologist, Henstedt-Ulzburg

  • Andrea Pahor, MD · MED Dep., AstraZeneca Germany

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2007-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607633 on ClinicalTrials.gov